Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, Orca BioSystems is raising $191,999,870.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Ivan Dimov played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Orca BioSystems

Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. Our manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling us to create proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. Our talented team is driven by a passion for science and compassion for patients.

To learn more about Orca BioSystems, visit http://orcabio.com/

Contact:
Ivan Dimov, President and Chief Executive Officer
510-501-1670
https://www.linkedin.com/in/ivdimov/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved